Cited by 4,148Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Innate and adaptive immune cells in the tumor microenvironment

Open access

Gajewski, Thomas F, Schreiber, Hans, Fu, Yang-Xin·2013·Nature Immunology

Open this paper in CoChat — free account

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2703

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,706
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J. D., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,674
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells
Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D. R., Benoist, C., & Mathis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.001 · Cited by 1,577
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,411
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Self-citation
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Писарев, В. М., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J. P., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,176
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,083
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,073
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon–Dependent Innate and Adaptive Immunity
Burnette, B., Liang, H. L., Lee, Y., Chlewicki, L. K., Khodarev, N. N., Weichselbaum, R. R., Fu, Y., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 883
Self-citation
Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M. D., Murali, R., McCarthy, S. W., Saw, R. P. M., & Thompson, J. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8539 · Cited by 857
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.014 · Cited by 818
Cancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C. B., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 790
Self-citation
Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells
Tan, J. T., Ernst, B., Kieper, W. C., LeRoy, E., Sprent, J., & Surh, C. D. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020066 · Cited by 790
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J. P., Alaparthy, S., Berman, D., Jure‐Kunkel, M., Siemers, N. O., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 783
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity
Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martínez, D., Hernanz-Falcón, P., Rosewell, I., & Sousa, C. R. E. (2009) · Nature · doi:10.1038/nature07750 · Cited by 750
Gastrosplenic Fistula From Hodgkin's Lymphoma
Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 736
Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Catani, J. P. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 727
NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence
Nielsen, M., Lundegaard, C., Blicher, T. H., Lamberth, K., Harndahl, M. N., Justesen, S. F. L., Røder, G., Peters, B., Sette, A., Lund, O., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000796 · Cited by 719
NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway
Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, L. C., Donaldson, D. D., Carbone, D. P., Paul, W. E., & Berzofsky, J. A. (2000) · Nature Immunology · doi:10.1038/82771 · Cited by 708
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells
Poulin, L. F., Salio, M., Griessinger, E., Anjos‐Afonso, F., Craciun, L., Chen, J., Keller, A. M., Joffre, O. P., Zelenay, S., Nye, E. L., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20092618 · Cited by 708
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C. D., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 653
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
Kreike, B., van Kouwenhove, M., Horlings, H. M., Weigelt, B., Peterse, H. L., Bartelink, H. G. M. M., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 622
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 596
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O’Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2007) · Nature Medicine · doi:10.1038/nm1699 · Cited by 566
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M., Thomas, B. A., Rupar, M. J., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 559
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin
Sancho, D., Mourão‐Sá, D., Joffre, O. P., Schulz, O., Rogers, N. C., Pennington, D. J., Carlyle, J. R., & Sousa, C. R. E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34584 · Cited by 543
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C. E., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 541
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J., & Swartz, M. A. (2010) · Science · doi:10.1126/science.1185837 · Cited by 530
l -Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes
Rodrı́guez, P. C., Zea, A. H., DeSalvo, J., Culotta, K. S., Zabaleta, J., Quiceno, D. G., Ochoa, J. B., & Ochoa, A. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1232 · Cited by 494
The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation
Chen, W., Liang, X., Peterson, A. J., Munn, D. H., & Blazar, B. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5396 · Cited by 472
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd, M. C., Schell, M. J., Sondak, V. K., Weber, J. S., & Mulé, J. J. (2012) · Scientific Reports · doi:10.1038/srep00765 · Cited by 426
Tumor-Infiltrating γδ T Cells Suppress T and Dendritic Cell Function via Mechanisms Controlled by a Unique Toll-like Receptor Signaling Pathway
Peng, G., Wang, H. Y., Peng, W., Kiniwa, Y., Seo, K. H., & Wang, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.020 · Cited by 419
Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma
Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P. J., Mottram, P. J., Curiel, T. J., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 409
F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells
Ahrens, S., Zelenay, S., Sancho, D., Hanč, P., Kjær, S., Feest, C., Fletcher, G., Durkin, C. H., Postigo, A. A., Skehel, M. J., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.008 · Cited by 393
Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression
Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi‐Galy, S. I., Goddard‐Léon, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3468 · Cited by 377
Type I interferon response and innate immune sensing of cancer
Fuertes, M. B., Woo, S.-R., Burnett, B., Fu, Y.-X., & Gajewski, T. F. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.004 · Cited by 375
Self-citation
Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.
Quatromoni, J. G., & Eruslanov, E. B. (2012) · Europe PMC (PubMed Central) · Cited by 361
Priming of naive T cells inside tumors leads to eradication of established tumors
Yu, P., Lee, Y., Liu, W., Chin, R., Wang, J. H., Wang, Y., Schietinger, A., Philip, M., Schreiber, H. W., & Fu, Y. (2004) · Nature Immunology · doi:10.1038/ni1029 · Cited by 354
Self-citation
An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium
Johnson, L. A., Clasper, S., Holt, A. P., Lalor, P. F., Baban, D., & Jackson, D. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051759 · Cited by 346
CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
Rech, A. J., Mick, R., Martin, S., Recio, A., Aqui, N. A., Powell, D. J., Colligon, T. A., Trosko, J. A., Leinbach, L. I., Pletcher, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003330 · Cited by 344
NKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J. B., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 344
CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Delahaye, N. F., Rusakiewicz, S., Martins, I., Menard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 338
β-Catenin induces immortalization of melanocytes by suppressing p16 INK4a expression and cooperates with N-Ras in melanoma developmentPreprint
Delmas, V., Beermann, F., Martinozzi, S., Carreira, S., Ackermann, J., Kumasaka, M. Y., Denat, L., GOODALL, J. C., Luciani, F., Virós, A., et al. (2007) · Genes & Development · doi:10.1101/gad.450107 · Cited by 336
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?
Bui, J. D., & Schreiber, R. D. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.001 · Cited by 319
Plasmacytoid dendritic cells induce NK cell–dependent, tumor antigen–specific T cell cross-priming and tumor regression in mice
Liu, C., Lou, Y., Lizee, G. A., Qin, H., Liu, S., Rabinovich, B. A., Kim, G. J., Wang, Y.-H., Ye, Y., Sikora, A. G., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33583 · Cited by 317
Prevention of T Cell Anergy by Signaling Through the γ c Chain of the IL-2 Receptor
Boussiotis, V. A., Barber, D. L., Nakarai, T., Freeman, G. J., Gribben, J. G., Bernstein, G. M., D’Andrea, A. D., Ritz, J., & Nadler, L. M. (1994) · Science · doi:10.1126/science.7973657 · Cited by 307
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, Á., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 305
The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice
Zelenay, S., Keller, A. M., Whitney, P. G., Schraml, B. U., Deddouche, S., Rogers, N. C., Schulz, O., Sancho, D., & Sousa, C. R. E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60644 · Cited by 290
Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma
Attia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L. J., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175468.19742.10 · Cited by 286
Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer
Narra, K., Mullins, S., Lee, H.-O., Strzemkowski-Brun, B., Magalong, K., Christiansen, V. J., McKee, P. A., Egleston, B. L., Cohen, S. J., Weiner, L. M., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.11.4874 · Cited by 285
Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation
Zhou, X., Gimm, O., Hampel, H., Niemann, T. H., Walker, M. J., & Eng, C. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64627-5 · Cited by 278
The WNT/Beta-catenin pathway in melanoma
Larue, L. (2006) · Frontiers in bioscience · doi:10.2741/1831 · Cited by 257
Cytoplasmic DNA innate immune pathways
Barber, G. N. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01051.x · Cited by 254
DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues
Poulin, L. F., Reyal, Y., Uronen‐Hansson, H., Schraml, B. U., Sancho, D., MURPHY, K. M. M., Håkansson, U., Moita, L. F., Agace, W. W., Bonnet, D. A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-406967 · Cited by 251
Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy
Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Self-citation
A unique tumor antigen produced by a single amino acid substitution
Monach, P. A., Meredith, S. C., Siegel, C., & Schreiber, H. W. (1995) · Immunity · doi:10.1016/1074-7613(95)90078-0 · Cited by 242
Self-citation
Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment
Gajewski, T. F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0892 · Cited by 235
Self-citation
Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy
Sportès, C., Babb, R. R., Krumlauf, M., Hakim, F. T., Steinberg, S. M., Chow, C. K., Brown, M. R., Fleisher, T. A., Noël, P., Marić, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1303 · Cited by 227
High endothelial venules (HEVs) in human melanoma lesions
Martinet, L., Guellec, S. L., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 206
Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma
Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N., & Tanabe, K. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1021-7 · Cited by 203
Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells
Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M., & Hanahan, D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021047 · Cited by 180
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini, R., Piris, A., Maurichi, A., Molla, A., Bersani, I., Bono, A. V., Bartoli, C., Santinami, M., Lombardo, C., Ravagnani, F., et al. (2003) · PubMed · Cited by 177
Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms
Demoulin, S., Herfs, M. F., Delvenne, P., & Hubert, P. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0812397 · Cited by 170
Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.
Singh, S., Ross, S. R., Acena, M., Rowley, D. A., & Schreiber, H. W. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.1.139 · Cited by 170
Self-citation
Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell–Mediated Killing
Liang, H. L., Deng, L., Chmura, S. J., Burnette, B., Liadis, N., Darga, T. E., Beckett, M. A., Lingen, M. W., Witt, M. E., Weichselbaum, R. R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202612 · Cited by 169
Self-citation
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity
Jinushi, M., Hodi, F. S., & Dranoff, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603503103 · Cited by 168
Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model
Wen, Y., Wang, C., Ma, T., Li, Z., Zhou, L., Mu, B., Leng, F., Shi, H., Li, Y., & Wei, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01695.x · Cited by 165
Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity
Mattarollo, S. R., Kenna, T., Nieda, M., & Nicol, A. J. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0279-2 · Cited by 165
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Richter, J. R., Neparidze, N., Zhang, L., Nair, S., Monesmith, T., Sundaram, R. K., Miesowicz, F., Dhodapkar, K. M., & Dhodapkar, M. V. (2012) · Blood · doi:10.1182/blood-2012-06-435503 · Cited by 164
Characterization of Tumor Reactivity of Human Vγ9Vδ2 γδ T Cells In Vitro and in SCID Mice In Vivo
Kabelitz, D., Wesch, D., Pitters, E., & Zöller, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6767 · Cited by 163
GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
Brichard, V. G., & Lejeune, D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.038 · Cited by 159
Transient T cell depletion causes regression of melanoma metastases
Rasku, M. A., Clem, A. L., Telang, S., Taft, B. S., Gettings, K. F., Gragg, H., Cramer, D. E., Lear, S. C., McMasters, K. M., Miller, D. M., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-12 · Cited by 158
Chimeric NK-receptor–bearing T cells mediate antitumor immunotherapy
Zhang, T., Lemoi, B. A., & Sentman, C. L. (2005) · Blood · doi:10.1182/blood-2004-11-4365 · Cited by 155
New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site
Appay, V., Jandus, C., Voelter, V., Reynard, S., Coupland, S. E., Rimoldi, D., Líénard, D., Guillaume, P., Krieg, A. Μ., Cerottini, J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1670 · Cited by 152
Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity
Engels, B., Engelhard, V. H., Sidney, J., Sette, A., Binder, D. C., Liu, R. B., Kranz, D. M., Meredith, S. C., Rowley, D. A., & Schreiber, H. W. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.018 · Cited by 149
Self-citation
IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk
Strasly, M., Cavallo, F., Geuna, M., Mitola, S. M. F., Colombo, M. P., Forni, G., & Bussolino, F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.6.3890 · Cited by 148
Redirecting αβT cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor
Marcu‐Malina, V., Heijhuurs, S., van Buuren, M., Hartkamp, L. M., Strand, S., Sebestyén, Z., Scholten, K. B. J., Martens, A. C., & Kuball, J. H. E. (2011) · Blood · doi:10.1182/blood-2010-12-325993 · Cited by 148
Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites
Harlin, H., Kuna, T. V., Peterson, A., Meng, Y., & Gajewski, T. F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0118-2 · Cited by 144
Self-citation
Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells in the Induction of Antigen-Specific Antitumor Immune Responses
Lou, Y., Liu, C., Kim, G. J., Liu, Y., Hwu, P., & Wang, G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1534 · Cited by 134
Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects
Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131
Type I natural killer T cells suppress tumors caused by p53 loss in mice
Swann, J. B., Uldrich, A. P., van Dommelen, S. L. H., Sharkey, J., Murray, W. K., Godfrey, D. I., & Smyth, M. J. (2009) · Blood · doi:10.1182/blood-2009-01-198564 · Cited by 126
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
Petrella, T. M., Tozer, R. G., Bélanger, K., Savage, K. J. J., Wong, R., Smylie, M., Kamel‐Reid, S., Tron, V. A., Chen, B. E., Hunder, N. N. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0655 · Cited by 126
RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry
Jung, H., Hsiung, B., Pestal, K., Procyk, E., & Raulet, D. H. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120565 · Cited by 123
Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity
Edosada, C. Y., Quan, C. L., Wiesmann, C., Tran, T., Sutherlin, D., Reynolds, M., Elliott, J. M., Raab, H. E., Fairbrother, W. J., & Wolf, B. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511112200 · Cited by 114
From defined human tumor antigens to effective immunization?
Boon, T., Gajewski, T. F., & Coulie, P. G. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80149-9 · Cited by 113
Self-citation
Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma
Massi, D., Tarantini, F., Franchi, A., Paglierani, M., Serio, C. D., Pellerito, S., Leoncini, G., Cirino, G., Geppetti, P., & Santucci, M. (2005) · Modern Pathology · doi:10.1038/modpathol.3800526 · Cited by 101
Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment
Barber, A., Rynda, A., & Sentman, C. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902000 · Cited by 101
Chemotherapy-Induced Genotoxic Stress Promotes Sensitivity to Natural Killer Cell Cytotoxicity by Enabling Missing-Self Recognition
Fine, J. H., Chen, P., Mesci, A., Allan, D., Gasser, S., Raulet, D. H., & Carlyle, J. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1316 · Cited by 100
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection
Brown, I. E., Blank, C., Kline, J., Kacha, A. K., & Gajewski, T. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4521 · Cited by 91
Self-citation
Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
Kline, J. P., Brown, I. E., Zha, Y.-Y., Blank, C. U., Strickler, J. H., Wouters, H., Zhang, L., & Gajewski, T. F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4696 · Cited by 89
Self-citation
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy
Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0407-z · Cited by 88
Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases
Yü, P., Lee, Y., Wang, Y., Liu, X., Auh, S. L., Gajewski, T. F., Schreiber, H. W., You, Z., Kaynor, C., Wang, X., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1960 · Cited by 79
Self-citation
Functional differences between low- and high-affinity CD8+T cells in the tumor environment
Bos, R., Marquardt, K., Cheung, J., & Sherman, L. A. (2012) · OncoImmunology · doi:10.4161/onci.21285 · Cited by 79
Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma
Zhang, B., Zhang, Y., Bowerman, N. A., Schietinger, A., Fu, Y., Kranz, D. M., Rowley, D. A., & Schreiber, H. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5324 · Cited by 77
Self-citation
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
Telang, S., Rasku, M. A., Clem, A. L., Carter, K., Klarer, A. C., Badger, W. R., Milam, R. A., Rai, S. N., Pan, J., Gragg, H., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-515 · Cited by 76
Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors
Russell, J. P., Shinohara, S., Melillo, R. M., Castellone, M. D., Santoro, M. M., & Rothstein, J. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206759 · Cited by 68
Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma
Dengel, L. T., Norrod, A. G., Gregory, B. L., Clancy‐Thompson, E., Burdick, M. D., Strieter, R. M., Slingluff, C. L., & Mullins, D. W. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fb045d · Cited by 68
Activated Stat-3 in Melanoma
Messina, J. L., Yu, H., Riker, A. I., Münster, P. N., Jove, R., & DAUD, A. I. (2008) · Cancer Control · doi:10.1177/107327480801500302 · Cited by 68
Local IL-21 Promotes the Therapeutic Activity of Effector T cells by Decreasing Regulatory T Cells Within the Tumor Microenvironment
Kim‐Schulze, S., Kim, H. S., Fan, Q., Kim, D. W., & Kaufman, H. L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.249 · Cited by 66
The confluence of radiotherapy and immunotherapy
Burnette, B., Fu, Y., & Weichselbaum, R. R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00143 · Cited by 65
Self-citation
Role of γδ T Cells in α-Galactosylceramide–Mediated Immunity
Paget, C., Chow, M. T., Duret, H., Mattarollo, S. R., & Smyth, M. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103582 · Cited by 58
IFN-γ-Producing Human Invariant NKT Cells Promote Tumor-Associated Antigen-Specific Cytotoxic T Cell Responses
Moreno, M., Molling, J. W., von Mensdorff‐Pouilly, S., Verheijen, R. H. M., Hooijberg, E., Kramer, D., Reurs, A. W., van den Eertwegh, A. J. M., Blomberg, B. M. E. V., Scheper, R. J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2446 · Cited by 55
Densely Granulated Murine NK Cells Eradicate Large Solid Tumors
Liu, R. B., Engels, B., Arina, A., Schreiber, K., Hyjek, E. M., Schietinger, A., Binder, D. C., Butz, E. A., Krausz, T. N., Rowley, D. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3208 · Cited by 54
Self-citation
Innate immune sensing of cancer: clues from an identified role for type I IFNs
Gajewski, T. F., Fuertes, M. B., & Woo, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1305-6 · Cited by 52
Self-citation
Mechanisms of the Antitumor Activity of Human Vγ9Vδ2 T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma
Carlo, E. D., Bocca, P., Emionite, L., Cilli, M., Cipollone, G., Morandi, F., Raffaghello, L., Pistoia, V., & Prigione, I. (2013) · Molecular Therapy · doi:10.1038/mt.2013.38 · Cited by 52
Detection of TSPY protein in a unilateral microscopic gonadoblastoma of a Turner mosaic patient with a Y‐derived marker chromosome
Hildenbrand, R., Schröder, W., Brude, E., Schepler, A., König, R., Stutte, H. J., & Arnemann, J. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199912)189:4 · Cited by 46
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy
Zheng, Y., Zha, Y., Spaapen, R. M., Mathew, R. S., Barr, K., Bendelac, A. S., & Gajewski, T. F. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.03.006 · Cited by 45
Self-citation
IRF5 gene polymorphisms in melanoma
Uccellini, L., Giorgi, V. D., Zhao, Y., Tumaini, B., Erdenebileg, N., Dudley, M. E., Tomei, S., Bedognetti, D., Ascierto, M. L., Liu, Q., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-170 · Cited by 41
Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles
Mortarini, R., Scarito, A., Nonaka, D., Zanon, M., Bersani, I., Montaldi, E., Pennacchioli, E., Patuzzo, R., Santinami, M., & Anichini, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3239 · Cited by 39
A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response
Sullivan, R. J., Hoshida, Y., Brunet, J.-P., Tahan, S. R., Aldridge, J., Kwabi, C., Gardiner, E., McDermott, D. F., Golub, T. R., & Atkins, M. B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9003 · Cited by 39
NK Cells and γδ T Cells Mediate Resistance to Polyomavirus–Induced Tumors
Mishra, R., Chen, A. T., Welsh, R. M., & Szomolanyi‐Tsuda, E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000924 · Cited by 38
Vaccination with Antigen-Transfected, NKT Cell Ligand–Loaded, Human Cells Elicits Robust In Situ Immune Responses by Dendritic Cells
Shimizu, K., Mizuno, T., Shinga, J., Asakura, M., Kakimi, K., Ishii, Y., Masuda, K., Maeda, T., Sugahara, H., Sato, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0759 · Cited by 37
Critical Role of CD11a (LFA-1) in Therapeutic Efficacy of Systemically Transferred Antitumor Effector T Cells
Mukai, S., Kagamu, H., Shu, S., & Plautz, G. E. (1999) · Cellular Immunology · doi:10.1006/cimm.1998.1439 · Cited by 33
Oncoprotein Signaling Mediates Tumor-Specific Inflammation and Enhances Tumor Progression
Pufnock, J., & Rothstein, J. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801284 · Cited by 24
Recognition of Shared Melanoma Antigens by Human Tumor-Infiltrating Lymphocytes
Topalian, S. L., Horn, S. S., Kawakami, Y., Mancini, M., Schwartzentruber, D. J., Zakut, R., & Rosenberg, S. A. (1992) · Journal of Immunotherapy · doi:10.1097/00002371-199210000-00013 · Cited by 23

Flagged first, then by citations

Research works printed but not linked: 1

Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. (in the press).

Sorted by citations

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
“However, even early on, there is also engagement of cells of the acquired system—particularly T cells (Gajewski et al., 2013).”
BackgroundInfluential

See all 4,148

Authors: Gajewski, T. F., Schreiber, H., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Gajewski, Thomas F
ORCID: Schreiber, Hans
Fu, Yang-Xin
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-09-18
Volume: 14
Issue: 10
Pages: 1014-1022
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2703
PMC: PMC4118725
OpenAlex: W2042699075
Cited by: 4,148
References: 149
Citations by year: 2026: 187 · 2025: 310 · 2024: 432 · 2023: 486 · 2022: 443 · 2021: 522 · 2020: 372 · 2019: 315 · 2018: 290 · 2017: 290 · 2016: 240 · 2015: 162 · 2014: 82 · 2013: 1
FWCI: 17.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA161005, R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: tumor microenvironment, tumor immune evasion, innate immunity, adaptive immunity, CD8+ T cells, immune exclusion, type I interferon signature, chemokine profile, immune checkpoint blockade, cancer immunotherapy
MeSH terms: Animals, Dendritic Cells, Humans, Immunity, Innate, Lymphocyte Activation, Neoplasms, T-Lymphocyte Subsets, Stromal Cells, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Innate and adaptive immune cells in the tumor microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks